SHH:600329
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited · SHH · Healthcare · CNY · FY for 2025
Figures on this page computed 2026-11-07 23:08 UTC
Last close
n/aCNY
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
15.2xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
34.4%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
43.3%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
7.0%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
0.01Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
3.0%Dividend yield
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
What it pays out is the furthest below its sector's middle: 0.40 against 0.44 on the market's range.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2025
- Sales0.73x
Its own average over 10 years, 6.75B.
- Profit2.19x
Its own average over 10 years, 972.7M.
- Free cash flow0.84x
Its own average over 10 years, 409.3M.
- Debt0.39x
Its own average over 10 years, 159.1M.
- Pricen/a
Its own average over 0 years. Market data
Profit is furthest from its own average, at 2.19 times.
The filed years, as a table
10Each line is 100 at 2016-12-31, the first year we hold.
| Filed year | Sales | Profit | Shares in issue |
|---|---|---|---|
| 2016-12-31 | 100.0 | 100.0 | 100.0 |
| 2017-12-31 | 91.1 | 112.4 | 99.7 |
| 2018-12-31 | 101.9 | 132.6 | 99.9 |
| 2019-12-31 | 112.0 | 147.7 | 99.8 |
| 2020-12-31 | 105.8 | 156.2 | 99.8 |
| 2021-12-31 | 110.7 | 181.6 | 99.8 |
| 2022-12-31 | 132.1 | 203.4 | 100.8 |
| 2023-12-31 | 131.7 | 232.9 | 100.1 |
| 2024-12-31 | 117.0 | 526.3 | 100.2 |
| 2025-12-31 | 78.8 | 503.1 | 99.9 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
How profit was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Figures behind the shape
Growth
-5.7%faster is higher, placed against 4,950 companies as of 2026-11-06
Five-year revenue growth rate-5.7%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Five-year EPS growth rate26.4%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
One-year change in net income-4.4%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Returns on capital
34.4%higher is higher, placed against 5,089 companies as of 2026-11-06
Return on invested capital34.4%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity30.0%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets18.2%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Margins
74.0%wider is higher, placed against 3,412 companies as of 2026-11-06
Gross margin74.0%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin50.6%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin43.3%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin7.0%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Price
15.2xcheaper is higher, placed against 4,362 companies as of 2026-11-06
Price to earnings15.2x
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
Price to book4.6x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDA12.0x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio6.6x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
Safety
0.01safer is higher, placed against 3,227 companies as of 2026-11-06
Debt to equity0.01
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio1.59
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage271.7x
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score6.22
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
What it pays out
3.0%more, and better covered, is higher, placed against 1,091 companies as of 2026-11-06
Dividend yield3.0%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Payout ratio46.0%
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ratio0.3x
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.